Pyxis Oncology, Inc. — Form 8-K
Filed November 19, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Pyxis announced updated Phase 1 monotherapy results for MICVO in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma as of October 14, 2026 (N=33 efficacy-evaluable patients dosed at 5.4 mg/kg Q3W with dose cap). Key data: 39% confirmed ORR, 94% disease control rate, 6.7-month median PFS (vs. 4.2 months on prior therapy—a 50% improvement), 9.2-month median duration of response, and 81% 12-month OS probability. Safety: manageable; six Grade 3 peripheral neuropathy cases all resolved or improved. Company plans Phase 3 initiation mid-2027.
Why this rating
Clinical de-risking of lead asset with Phase 3-enabling data; material for $64.4M company. Positive efficacy/safety profile supports pivotal advancement, though early-stage biotech execution risk remains.
Tradability signal
NO TRADE
No trade: the filing reads positive but the market is selling it (-4.4% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $1.40 | +10 min · unknown $1.42 ▲ 1.43% | +30 min · unknown $1.40 ▼ 0.07% | +1 hr · unknown $1.42 ▲ 1.43% | +4 hrs · unknown $1.45 ▲ 3.57% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.